Literature DB >> 9074430

Acquired von Willebrand's disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells.

A Tefferi1, C A Hanson, P J Kurtin, J A Katzmann, R J Dalton, W L Nichols.   

Abstract

A 69-year-old woman presented with splenic marginal zone lymphoma associated with acquired von Willebrand's disease (AVWD). Laboratory abnormalities included markedly decreased plasma levels of factor VIII coagulant (C) activity (VIII:C 28%), von Willebrand's factor (VWF) antigen (Ag) (vWF:Ag < 6%), and VWF ristocetin cofactor (RCo) activity (VWF:RCo, < 12%). VWF multimer analysis revealed a severe type II defect. Treatment with cryoprecipitate, high-dose gamma globulin or desmopressin given intravenously was unsuccessful. Clinical bleeding and coagulation abnormalities showed transient improvement after replacement therapy with Humate-P concentrate. The coagulation abnormalities improved partially after splenectomy and completely after subsequent chemotherapy. The neoplastic lymphocytes in the blood and spleen strongly expressed platelet glycoprotein Ib (CD42) and VWF but not other platelet-associated antigens.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9074430     DOI: 10.1046/j.1365-2141.1997.d01-2088.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

Review 1.  Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.

Authors:  Hiroshi Mohri
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

2.  Successful treatment of a noninhibitory antibody-mediated acquired factor X deficiency in a patient with marginal-zone lymphoma.

Authors:  Annemarie Meenhuis; Rianne van Vliet; Francisca Hudig; Paula F Ypma; Martin R Schipperus; Martine J Hollestelle
Journal:  Clin Case Rep       Date:  2015-05-25

3.  Splenic Marginal Zone Lymphoma with Acquired von Willebrand Syndrome Diagnosed via Splenic Bleeding.

Authors:  Yukiko Komeno; Naoki Shibuya; Hideki Uryu; Haruki Yamada; Takeo Toda; Masayuki Shibasaki; Shinji Kunishima; Kuniko Iihara; Tomiko Ryu
Journal:  Intern Med       Date:  2017-03-01       Impact factor: 1.271

4.  Acquired von Willebrand Disease Associated with Mantle Cell Lymphoma.

Authors:  Dominique Maas; Britta Laros-van Gorkom; Sanne Gianotten; Marjan Cruijsen; Waander van Heerde; Marten Nijziel
Journal:  Case Rep Hematol       Date:  2018-01-30

Review 5.  The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer.

Authors:  Chanukya K Colonne; Emmanuel J Favaloro; Leonardo Pasalic
Journal:  Healthcare (Basel)       Date:  2022-03-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.